Inflammation Markers After Randomization to Abacavir/lamivudine or Tenofovir/emtricitabine with Efavirenz or Atazanavir/ritonavir

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2012 May 2

PMID 22546988

Citations 55

Authors

Grace A McComsey

Douglas Kitch

Eric S Daar

Camlin Tierney

Nasreen C Jahed

Kathleen Melbourne

Belinda Ha

Todd T Brown

Anthony Bloom

Neal Fedarko

Paul E Sax

Affiliations

Soon will be listed here.

Abstract

Background: The effect of specific antiretrovirals on inflammation is unclear.

Methods: A5224s was a substudy of A5202, which randomized HIV-infected treatment-naïve patients to blinded abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in a factorial design. Our analysis compared changes in inflammation markers from baseline to week 24 between ABC/3TC and TDF/FTC. Secondary analyses included changes at week 96 and comparisons of EFV vs. ATV/r.

Results: Analyses included 244 patients (85% male, 48% white non-Hispanic), median age 39 years, HIV-1 RNA 4.6 log10 copies/ml, CD4 240 cells/μl. TNF-α, soluble receptors of TNF-α (sTNFR)-I and II, soluble vascular cellular adhesion molecule (sVCAM)-1 and soluble intercellular adhesion molecule (sICAM)-1 decreased significantly at weeks 24 and 96, without significant differences between components (P ≥ 0.44). At week 24, ABC/3TC had a greater high-sensitivity C-reactive protein (hsCRP) mean fold change than TDF/FTC {1.43 vs. 0.88, estimated mean fold change percentage difference [Δ] 61.5% [95% confidence interval (CI) 13.6%, 129.5%]; P = 0.008}. Similar results were seen at week 96 (P = 0.021). At week 24 (but not 96), EFV had a greater hsCRP mean fold change than ATV/r [1.41 vs. 0.88; Δ = 60.2% (12.6%, 127.7%); P = 0.009]. IL-6 decreased significantly at week 24 with TDF/FTC but not with ABC/3TC (between-components P = 0.019). At week 96, IL-6 decreased significantly in both nucleoside reverse transcriptase inhibitor components (between-components P = 0.11). IL-6 changes were not significantly different between ATV/r and EFV at either time point (P ≥ 0.89).

Conclusions: Soluble TNF-receptors and adhesion molecules decreased following treatment initiation and did not differ by regimens. Differences were seen on hsCRP and IL-6 changes with ABC/3TC vs. TDF/FTC and on hsCRP with EFV vs. ATV/r.

Citing Articles

Relationship between Modern ART Regimens and Immunosenescence Markers in Patients with Chronic HIV Infection.

Grozdeva R, Ivanov D, Strashimirov D, Kapincheva N, Yordanova R, Mihailova S Viruses. 2024; 16(8).

PMID: 39205179 PMC: 11360605. DOI: 10.3390/v16081205.

Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation.

Kosmider E, Wallner J, Gervassi A, Bender Ignacio R, Pinto-Santini D, Gornalusse G PLoS One. 2024; 19(7):e0288895.

PMID: 38976697 PMC: 11230552. DOI: 10.1371/journal.pone.0288895.

Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

Gonzalez-Cordon A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P J Antimicrob Chemother. 2023; 78(9):2361-2365.

PMID: 37539492 PMC: 7617418. DOI: 10.1093/jac/dkad247.

HIV, Combination Antiretroviral Therapy, and Vascular Diseases in Men and Women.

Kovacs L, Kress T, Belin de Chantemele E JACC Basic Transl Sci. 2022; 7(4):410-421.

PMID: 35540101 PMC: 9079796. DOI: 10.1016/j.jacbts.2021.10.017.

Coordination of inflammatory responses in children with perinatally acquired HIV infection.

Weinberg A, Giganti M, Sirois P, Montepiedra G, Canniff J, Agwu A AIDS. 2022; 36(8):1117-1127.

PMID: 35442223 PMC: 9262767. DOI: 10.1097/QAD.0000000000003229.

References

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

Cauci S, Di Santolo M, Culhane J, Stel G, Gonano F, Guaschino S . Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol. 2008; 111(4):857-64. DOI: 10.1097/AOG.0b013e31816a2476. View

Palella Jr F, Gange S, Benning L, Jacobson L, Kaplan R, Landay A . Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010; 24(11):1657-65. PMC: 3514460. DOI: 10.1097/QAD.0b013e3283389dfa. View

Durand M, Sheehy O, Baril J, LeLorier J, Tremblay C . Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr. 2011; 57(3):245-53. DOI: 10.1097/QAI.0b013e31821d33a5. View

Sax P, Tierney C, Collier A, Fischl M, Mollan K, Peeples L . Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009; 361(23):2230-40. PMC: 2800041. DOI: 10.1056/NEJMoa0906768. View

Morabito L, Montesinos M, Schreibman D, Balter L, Thompson L, Resta R . Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998; 101(2):295-300. PMC: 508567. DOI: 10.1172/JCI1554. View

Sabin C, Worm S, Weber R, Reiss P, El-Sadr W, Dabis F . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371(9622):1417-26. PMC: 2688660. DOI: 10.1016/S0140-6736(08)60423-7. View

Pearson T, Mensah G, Alexander R, Anderson J, Cannon 3rd R, Criqui M . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499-511. DOI: 10.1161/01.cir.0000052939.59093.45. View

Ribaudo H, Benson C, Zheng Y, Koletar S, Collier A, Lok J . No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011; 52(7):929-40. PMC: 3062545. DOI: 10.1093/cid/ciq244. View

10.

Gallego-Escuredo J, Gutierrez M, Diaz-Delfin J, Domingo J, Gracia Mateo M, Domingo P . Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res. 2010; 8(7):545-53. DOI: 10.2174/157016210793499222. View

11.

Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A . Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease. Antivir Ther. 2007; 12(4):553-8. View

12.

Brown T, McComsey G, King M, Qaqish R, Bernstein B, da Silva B . Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51(5):554-61. DOI: 10.1097/QAI.0b013e3181adce44. View

13.

Choi A, Vittinghoff E, Deeks S, Weekley C, Li Y, Shlipak M . Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011; 25(10):1289-98. PMC: 3910369. DOI: 10.1097/QAD.0b013e328347fa16. View

14.

Landay A, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L . Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2003; 188(10):1444-54. DOI: 10.1086/379041. View

15.

Brown T, Tassiopoulos K, Bosch R, Shikuma C, McComsey G . Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010; 33(10):2244-9. PMC: 2945167. DOI: 10.2337/dc10-0633. View

16.

Buchbinder S, Kratzsch J, Fiedler G, Yar V, Brugel M, Leichtle A . Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest. 2007; 68(2):140-4. DOI: 10.1080/00365510701487727. View

17.

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P . Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy.... J Infect Dis. 2011; 203(12):1791-801. PMC: 3100514. DOI: 10.1093/infdis/jir188. View

18.

Triant V, Meigs J, Grinspoon S . Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009; 51(3):268-73. PMC: 2763381. DOI: 10.1097/QAI.0b013e3181a9992c. View

19.

Obel N, Farkas D, Kronborg G, Larsen C, Pedersen G, Riis A . Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2009; 11(2):130-6. DOI: 10.1111/j.1468-1293.2009.00751.x. View

20.

Kaplan R, Sinclair E, Landay A, Lurain N, Sharrett A, Gange S . T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011; 217(1):207-13. PMC: 3139014. DOI: 10.1016/j.atherosclerosis.2011.03.011. View